Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data
Pfizer’s attempt to catch up in the weight loss market picked up steam on Monday with research showing the company’s GLP-1 agonist helped people with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
